secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950170-24-027925
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%
----------------------------------------------------------------------------

- GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).
- Cash, equivalents, investments $218.1M at Dec 31, 2023; runway into early 2026.
- R&D expenses Q4 2023: $41.8M (up from $25.2M Q4 2022) due to more active trials.
- ASPEN-06 interim: ORR 52% evorpacept combo vs 22% control; mDOR not reached vs 7.4 mo.
- Anticipated milestones: ASPEN-06 top-line all 122 subjects June-July 2024; Phase 3 start Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/0000950170-24-027925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/alxo-20240307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer